Concepedia

Morten Bagger

MB

Statistics

Publications

11

Citations

418

H-Index

11

Active since

2001

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

University of Copenhagen

Heinrich Heine University Düsseldorf

Riverside Methodist Hospital

Morten Bagger is an author at Novartis (Switzerland) specializing in pharmacology, pharmacy, and pharmacokinetics.

Publications per year

2001–2022

11

Publications

11

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

Stephen L. Hauser, Anne H. Cross, Kevin Winthrop et al. · Multiple Sclerosis Journal · 2022 · 78 citations · Full text

, , +17

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study

Amit Bar‐Or, Heinz Wiendl, Xavier Montalbán et al. · Multiple Sclerosis Journal · 2021 · 62 citations · Full text

, , +17

The potential of nasal application for delivery to the central brain—a microdialysis study of fluorescein in rats

Morten Bagger, Erik Bechgaard · European Journal of Pharmaceutical Sciences · 2003 · 49 citations

, , +14

Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells

Anne Engelbrecht Thomsen, Michael Christensen, Morten Bagger et al. · European Journal of Pharmaceutical Sciences · 2004 · 42 citations

, , +17

Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis

Huixin Yu, Gordon Graham, Olivier J. David et al. · CNS Drugs · 2022 · 40 citations · Full text

, , +17

1–5 of 11